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Rotavirus is the leading cause of severe childhood
gastroenteritis. Each year, rotavirus is responsible for about 25
million clinic visits, two million hospital admissions, and 180
000-450 000 deaths in children under 5 years of age globally.1-3
Although rotavirus infection is prevalent worldwide, most deaths
from this infection occur in developing countries (fig 1⇓).
Gastroenteritis caused by rotavirus cannot be clinically
distinguished from that caused by other enteric pathogens;
diagnosis requires testing of fecal specimens with commercially
available assays. However, rotavirus is not routinely tested for
in patients with gastroenteritis because the results do not alter
clinical management, which relies mainly on appropriate
rehydration therapy. Orally administered live attenuated vaccines
that mimic natural infection offer the best protection against
rotavirus. Two licensed rotavirus vaccines have been available
since 2006 and have been implemented in many countries. We
review approaches to diagnosis, management, and prevention
of rotavirus gastroenteritis.
How does rotavirus gastroenteritis
present clinically?
The clinical spectrum of rotavirus infection ranges from
subclinical illness or mild watery diarrhea of limited duration
to frequent profuse diarrhea with vomiting and fever that can
result in dehydration with shock, electrolyte imbalance, and
death. Rotavirus illness usually begins with acute onset of fever
and vomiting, followed one or two days later by frequent watery
stools. About 30-40% of children may have a moderate fever
(temperature >39°C). Vomiting usually lasts for only one or
two days and other gastrointestinal symptoms generally resolve
in three to seven days.
Although gastroenteritis is the chief manifestation of rotavirus
infection, neurologic features—including benign convulsions
(usually afebrile but febrile in some cases), encephalitis or
encephalopathy, and cerebellitis—have also been described.4
For example, a multicentre study fromCanada reported that 7%
of 1359 children admitted to hospital with laboratory confirmed
rotavirus had seizures at presentation.5A variety of other clinical
conditions (such as sudden infant death syndrome, necrotizing
enterocolitis, intussusception, Kawasaki’s disease, and type 1
diabetes) have been associated with rotavirus gastroenteritis,
but a causal association has not been confirmed. A transient rise
in serum transaminase concentrations is also often seen in
patients with rotavirus gastroenteritis.
Who gets rotavirus disease?
Rotavirus infects nearly all children in developed and developing
countries by 3-5 years of age. Neonatal infections occur but are
often asymptomatic or mild, possibly because of protection
from maternal antibody. The incidence of clinical illness peaks
in children aged 4-23 months, who are also at greatest risk of
severe disease that requires hospital admission. Although repeat
infections are common (three or more rotavirus infections
occurred in about 42% of children by 2 years of age in one
follow-up study in a cohort of Mexican children), symptoms
are milder with each subsequent infection.6 7Therefore, rotavirus
infections are usually subclinical or mild in adults, but they can
be severe, particularly in immunocompromised and older
people.8 Rotavirus is also an important cause of nosocomial
diarrhea.
Case-control studies in industrialized countries have shown that
lack of breast feeding, prematurity, and low birth weight are
associated with increased risk of hospital admission for rotavirus
gastroenteritis.9 10 Protracted rotavirus diarrhea with prolonged
viral excretion and, in rare instances, systemic dissemination
has been described in severely immunodeficient children,
particularly those with severe T cell and combined T and B cell
deficiencies. People who are immunosuppressed in preparation
for bone marrow transplantation are also at risk for severe or
even fatal rotavirus disease.
In all regions of the world, rotavirus is the leading cause of
hospital admission for gastroenteritis. A systematic review of
131 surveillance studies published from 2001 to 2011 found
that rotavirus accounted for 33-49% of hospital admissions for
gastroenteritis in countries in different geographic regions and
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Summary points
Rotavirus is the leading cause of severe gastroenteritis in children worldwide, accounting for 35-40% of hospital admissions for
gastroenteritis
Each year, 180 000-450 000 children under 5 years die from rotavirus gastroenteritis, with more than 90% of deaths occurring in
developing countries
Because nearly all children are affected by rotavirus by age 5 years, good sanitation and hygiene alone are inadequate for prevention
Orally administered live attenuated vaccines offer the best protection against rotavirus; as of December 2013, national immunization
programs of 51 countries include rotavirus vaccine
Such programs have greatly reduced morbidity and mortality from gastroenteritis
A low risk of intussusception has also been documented post-licensure in some countries, but this risk is greatly exceeded by the health
benefits of vaccination
Sources and selection criteria
We looked at recent conference proceedings and searched PubMed, the Cochrane Database of Systematic Reviews, and Clinical Evidence
online using the terms “rotavirus”, “rotavirus gastroenteritis”, and “rotavirus vaccines”. We focused on systematic reviews, meta-analyses,
and high quality randomized controlled trials published in English within the past 10 years (2004-13).
with varying levels of child mortality.2 However, more than
90% of global deaths from rotavirus occur in low income
countries in sub-Saharan Africa and South Asia, mainly because
of suboptimal access to healthcare, including basic hydration
therapy. In addition, compared with industrialized countries,
severe rotavirus gastroenteritis occurs at a younger age in
developing countries (up to two thirds of all paediatric disease
occurs in the first year of life) and coinfections with other enteric
pathogens are more common.
In temperate climates, rotavirus gastroenteritis shows prominent
seasonality, occurring mainly during the fall and winter, with
little disease activity during summer months.11 In tropical
countries, rotavirus occurs all year round, although incidence
often increases during the cool dry months.
How do rotaviruses cause diarrhea?
Mechanisms of rotavirus pathogenesis have been studied in
animal models and humans. The infectious dose of rotavirus is
estimated to be 100-1000 viral particles.12 Transmission of
rotavirus occurs mainly through the fecal-oral route, and viral
spread can occur through contaminated hands, environmental
surfaces and objects, and occasionally food and water. Rotavirus
exclusively infects the mature differentiated enterocytes found
at the tips of the villi in the small intestine (fig 2⇓). Attachment
of rotavirus to its sialoglycoprotein and integrin receptors is
mediated mainly by viral protein 4 (VP4), but neutralizing
antibodies directed against VP4 or VP7 (or both) can prevent
viral binding and penetration. Infection of the enterocyte leads
to virus entry, uncoating of the virus, transcription of nucleic
acid, translation of viral proteins, formation of viroplasms, and
apical release of the virus and viral protein by a non-classic
secretory pathway.13 The progeny virus are produced after 10-12
hours and released in large numbers into the intestinal lumen.
Rotavirus can infect neighboring cells, leading to continued
replication and shedding, which consists initially of a high viral
load. In children, the viral load decreases rapidly as diarrhea
resolves, but viral nucleic acid can be detected at low levels for
several weeks.14
The pathogenesis of rotavirus diarrhea includes effects on
absorption and on secretion.Morphologically, rotavirus infection
causes enterocyte death and desquamation, leading to the loss
of absorptive villous cells and the proliferation of secretory
crypt cells.15Malabsorption may also result from a virus induced
reduction in the expression of absorptive enzymes, as well as
paracellular leakage as a consequence of functional changes in
tight junctions between enterocytes, which may be mediated by
the viral non-structural protein 4 (NSP4). Biopsies show atrophy
of the villi and mononuclear cell infiltrates in the lamina propria.
Increased chloride secretion and loss of consequent water and
electrolyte are mediated by NSP4, which acts as a viral
enterotoxin, activating cellular calcium channels and inducing
secretory diarrhea. Activation of the enteric nervous system
(also thought to be dependent on NSP4) induces secretory
diarrhea and increases intestinal motility.13Villous brush border
enzymes such as sucrase and isomaltase also decrease, resulting
in accumulation of undigested sugars in the intestinal lumen.
This increases the osmotic gradient, which in turn favours further
fluid secretion.
Rotavirus infection was previously thought to be limited to the
intestine, but several studies over the past decade have shown
that rotavirus causes short term viremia in immunocompetent
infants as well as in experimentally infected animals.16 The
clinical relevance of this systemic spread of rotavirus remains
unclear, but it may be linked to the extraintestinal clinical
manifestations associated with rotavirus infection.
How is rotavirus diagnosed?
Rotavirus can be detected in stool specimens from children with
gastroenteritis by several techniques, including electron
microscopy, polyacrylamide gel electrophoresis, antigen
detection assays, reverse transcription polymerase chain reaction
(RT-PCR), and virus isolation. Diagnosis of rotavirus was
initially by electron microscopy, with and without agglutination
by immune sera. Large numbers of rotavirus particles (up to
1011/g feces) are excreted during the acute phase of infection,
and children with severe diarrhea seem to excrete a greater
number of viruses.17 Polyacrylamide gel electrophoresis detects
rotavirus RNA extracted directly from stool specimens; the
electrophoretic migration pattern of the 11 segments of the
double stranded RNAgenome permits analysis of the relatedness
of circulating strains.18
Children with gastroenteritis are not routinely tested for rotavirus
because the results do not alter treatment. When testing is
performed, antigen detection tests—including commercially
available enzyme linked immunosorbent assays (ELISAs) and
immunochromatographic assays—are widely used. Most of
these tests have high sensitivity and specificity (90-95%).19
RT-PCR is widely used in research laboratories to detect the
viral genome.20 It provides data on the VP7 and VP4 genotypes
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that form the basis of binary classification (G and P type,
respectively) of rotavirus strains.
How is rotavirus gastroenteritis treated?
The management of acute rotavirus gastroenteritis focuses on
the treatment and prevention of dehydration. In most situations
the clinician will not be aware at the start of treatment whether
the gastroenteritis is caused by rotavirus or another pathogen.
Initial assessment therefore focuses on determining the degree
of dehydration because this will be used to guide and monitor
treatment.
Many evidence based reviews and clinical guidelines are
available on various aspects of the assessment and treatment of
acute gastroenteritis in young children.21-36 However, a recent
systematic review of eight guidelines noted considerable
variation in their quality, inconsistencies between the
recommendations, lack of evidence for many recommendations,
and lack of generalisability to general practice.37 These were
suggested as possible reasons why adherence to such guidelines
is poor in high income countries. For example, the authors noted
that in general practice it was unclear “how” or to “whom” oral
rehydration therapy should be given. They concluded that future
studies, particularly in general practice, need to determine the
value of clinical signs and symptoms in assessing dehydration,
the optimal dose of oral rehydration solution for each grade of
dehydration, and the validity of reasons why clinicians prescribe
other drugs. In contrast, another recent assessment of the quality
of clinical practice guidelines for acute gastroenteritis, using
the appraisal of guidelines for research and evaluation
instrument, concluded that the overall quality of these guidelines
was fair.38
How should dehydration be assessed?
Several scoring systems have been devised to assess
dehydration.39 TheWorld Health Organization scale is probably
most widely used in the developing world (table 1⇓),40 whereas
the modified four point Gorelick score (box) and clinical
dehydration scale (table 2⇓) have been used in developed world
settings.32-34 39 The clinical dehydration scale has been reported
to help predict a longer length of stay and the need for
intravenous fluid rehydration.32 It is generally accepted that
conventional clinical signs of dehydration are valid and reliable
when used collectively but individually they lack sensitivity
and specificity.41 The Vesikari and Clark scores are used in
rotavirus vaccine efficacy trials for assessing the severity of
gastroenteritis but are not designed to guide clinical management
according to the degree of dehydration.35
Oral and intravenous rehydration therapy
Oral and intravenous rehydration is the mainstay of treatment
for rotavirus and other causes of acute gastroenteritis. Oral
rehydration therapy is the preferred treatment of mild to
moderate dehydration in children with acute diarrhea.27 29 41 For
every 25 children (95% confidence interval 14 to 100) treated
one will not respond and will require intravenous rehydration.27
Expert consensus recommends that children who are very ill,
lethargic, drinking poorly, or have shock or near shock are
initially treated intravenously. Oral rehydration therapy should
not be given to children with intestinal ileus until bowel sounds
are audible, or in the presence of glucose malabsorption.29
For more than two decades, WHO recommended the standard
glucose based oral rehydration solution (90 mmol/L sodium,
111 mmol/L glucose, and a total osmolarity 311 mmol/L).28
However, subsequent studies have shown that when compared
with the standard WHO solution, reduced osmolarity oral
rehydration solution is associated with fewer unscheduled
intravenous fluid infusions (odds ratio 0.59, 0.45 to 0.79), lower
stool volume after randomization, less vomiting, and no
increased risk of hyponatremia.28 In 2002, WHO recommended
the routine use of a solution with reduced osmolarity (sodium
75 mmol/L, glucose 75 mmol/L, and total osmolarity 224
mmol/L) for non-cholera diarrhea.
To maintain hydration of children with “no signs of
dehydration,” WHO recommends giving extra fluid or oral
rehydration solution after each loose stool. The suggested
volume is 50-100 mL (quarter to half a large cup) for children
under 2 years of age and a 100-200 mL (half to one large cup)
for those above 2.40 For children with “some signs of
dehydration,” WHO recommends correcting hydration over
four hours with 75 mL/kg of solution.40 However, a review of
eight international guidelines showed that recommendations on
the dose of oral rehydration solution were not evidence based
and were inconsistent, reflecting the use of expert opinion and
differences in how guidelines categorized dehydration.37 The
authors concluded that the optimal regimen was unclear.
It is important that breast feeding should continue throughout
the rehydration andmaintenance phases of treatment.40 Feeding
should be restarted as soon as possible because this will reduce
the duration and severity of diarrhea, and there is no evidence
that early refeeding increases the risk of unscheduled intravenous
fluid use, episodes of vomiting, or development of persistent
diarrhea.22Although lactose-free feeds may reduce the duration
of diarrhea in children withmild to severe dehydration compared
with feeds containing lactose, there is no evidence that lactose
containing feeds are harmful for most children with acute
gastroenteritis.42
Randomized controlled trials—including some that specifically
assessed efficacy against rotavirus gastroenteritis—have shown
that other treatments such as probiotics, zinc, ondansetron,
nitazoxanide, and some biological compounds are effective in
the management of acute gastroenteritis.21 23 24 40-45 However,
recommendations for the use of these treatments vary
considerably between different developmental regions and
different countries, and further discussion of their use is beyond
the scope of this article.
How can rotavirus gastroenteritis be
prevented?
Because rotavirus infects nearly all children in both
industrialised and developing countries early in life, good
hygiene and sanitation alone are considered inadequate for
prevention. Observational studies have shown that breast feeding
confers protection from rotavirus gastroenteritis, although one
case-control study indicated that it may only postpone the
occurrence of rotavirus gastroenteritis to the post-weaning
period.46
Follow-up of birth cohorts indicates that, although children can
be infected with rotavirus four to five times in the first two years
of life, the incidence of severe rotavirus gastroenteritis is reduced
with each repeat infection.6 7 Therefore, orally administered,
live, attenuated rotavirus vaccines have been developed tomimic
the effect of natural infection and prevent severe rotavirus
disease.
A rhesus-human reassortant rotavirus vaccine (Rotashield,
Wyeth) was licensed in the US in 1998 after showing high
efficacy against severe rotavirus gastroenteritis in randomized
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Four point modified Gorelick score33 34
1 point for each of the signs listed below:
• Ill general appearance
• Absent tears
• Dry mucous membranes
• Capillary refill >2 s
≤1 points: maintain hydration (<5% dehydration).
2 points: needs oral rehydration (5-10% dehydration).
3-4 points with normal vital signs: needs intravenous rehydration (>10% dehydration).
Abnormal vital signs (increased heart rate, decreased blood pressure, decreased level of consciousness, increased
capillary refill time): needs resuscitation.
clinical trials.47 Rotashield was recommended for routine
immunization of US infants the same year but was abruptly
withdrawn a year later because post-licensure observational
studies found that it was associated with a severe adverse event,
intussusception.48 49 Intussusception is a form of bowel
obstruction that often requires surgery and is associated with
high fatality if not treated. It was estimated that vaccination of
10 000 infants with Rotashield resulted in one excess case of
intussusception.
Two other live oral rotavirus vaccines—a pentavalent
bovine-human reassortant vaccine (RotaTeq, Merck) and a
monovalent human vaccine (Rotarix, GSK Biologicals)—were
in advanced stages of clinical testing when Rotashield was
withdrawn (table 3⇓). RotaTeq and Rotarix were each tested in
randomized clinical trials of 60 000-70 000 infants to assess the
risk of intussusception before licensure.50 51 No increase in risk
was found during the 42 and 30 days post-vaccination after the
three doses of RotaTeq or two doses of Rotarix, respectively.
The vaccines showed 85-98% efficacy against severe rotavirus
gastroenteritis in these trials conducted in the Americas and
Europe, with good protection against disease caused by rotavirus
strains not included in the vaccines (heterotypic immunity).
These findings supported vaccine licensure and
recommendations for use by policy groups in the US and Europe
and by WHO.52
As of December 2013, 51 countries include rotavirus vaccines
in their national immunization programs. A systematic review
of ecologic studies from eight countries reported a 49-89%
decline in laboratory confirmed rotavirus hospital admissions
and 17-55% reduction in all cause hospital admissions for
gastroenteritis in children under 5 years within two years of
vaccine introduction.53 Unexpectedly, rotavirus vaccination of
young infants has also resulted in decreases in rotavirus disease
in children who missed vaccination, older children, and even
adults whowere not eligible for vaccination.54This phenomenon,
known as herd protection, is probably related to reduced
transmission of rotavirus in the community as a result of
vaccination. Reductions in nosocomial rotavirus infections have
also been seen since the introduction of the vaccine.55 Lastly,
ecologic studies from Mexico and Brazil have shown a 35%
and 22% decline in childhood deaths from diarrhea, respectively,
since the introduction of the vaccine,56 57 and these reductions
have been sustained for four years in Mexico. These findings
are particularly noteworthy because vaccine efficacy against
death from diarrhea was not evaluated in pre-licensure trials.
Post-licensure observational studies in several countries,
including the US, Australia, Mexico, and Brazil, have also
identified a low risk of intussusception with both rotavirus
vaccines.58-65The evidence of risk for the two vaccines is difficult
to compare directly because the study populations and designs
differed. In general, the overall risk is one to five excess cases
of intussusception per 100 000 vaccinated infants. Considering
the substantial and well documented health benefits of
vaccination against this low intussusception risk, policy makers
in countries with documented risk, as well as global health
authorities such asWHO, strongly support rotavirus vaccination
of infants.
Live oral vaccines against many diseases, such as polio, typhoid,
and cholera, have performed less well in developing countries
than in industrialised ones. The reasons for this variability are
not completely understood. Potential explanations include
interference in vaccine uptake by greater levels of maternal
antibody or concurrent enteric infections in developing countries,
as well as reduced immune response in infants because of
comorbidities or malnutrition, including micronutrient
deficiencies.66
Because of these concerns, randomised efficacy trials of both
RotaTeq and Rotarix were conducted in developing countries
in Africa and Asia.67-69 These trials showed modest vaccine
efficacy (50-64%) against severe rotavirus gastroenteritis.
Despite this reduced efficacy, the public health benefits of
vaccination in terms of number of severe rotavirus gastroenteritis
episodes prevented per 100 infants was greater in developing
than in industrialised countries. This is because of the
substantially greater rate of severe rotavirus gastroenteritis in
developing countries. These considerations led WHO to issue
a global recommendation for vaccination in 2009 and have
prompted several low income countries to include rotavirus
vaccination in their immunization programs.
As rotavirus vaccines are introduced into immunization
programs of low income countries globally, it will be important
to assess the real world impact of vaccination to gain a better
understanding of vaccine effectiveness and safety in a range of
settings. Although both of the licensed rotavirus vaccines have
shown good protection against a range of circulating rotavirus
strains, including strains with either or both G and P types not
contained in the vaccine, further monitoring of the long term
impact of vaccination on strain ecology is vital. Also, given the
moderate efficacy of rotavirus vaccines in low income countries,
interventions to improve vaccine performance (such as
additional vaccine doses or different vaccination schedules)
should be considered and evaluated. Finally, to sustain global
implementation of vaccination, an adequate supply of affordable
rotavirus vaccines must be assured. It is therefore encouraging
that several manufacturers in emergingmarkets, including India,
China, Indonesia, and Brazil, are developing candidate rotavirus
vaccines that may be available within the next five years.
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Areas for future research
Exploring the role of rotavirus in extraintestinal clinical syndromes (such as neurologic manifestations, necrotizing enterocolitis)
Investigating the value of clinical signs and symptoms in assessing dehydration, particularly in general practice
Defining the optimal dose of oral rehydration solution for each grade of dehydration, so that consistent recommendations can be made
Identifying treatments (including antiviral agents) with clinical efficacy against rotavirus gastroenteritis
Community based action research and sociocultural research on knowledge, attitudes, perceptions, cultural practices, and health seeking
behaviours with regard to rotavirus infection
Understanding the benefit-risk profile of routine rotavirus vaccination in a diverse range of geographic and socioeconomic settings
Investigating the effectiveness and impact of rotavirus vaccination in low income settings
Identifying interventions (such as additional vaccine doses or alternate schedules, supplementation with micronutrients) or alternative
approaches (such as parenteral vaccines) that might improve the performance of rotavirus vaccines in low income settings
Additional educational resources
Resources for healthcare professionals
Centers for Disease Control and Prevention. Prevention of rotavirus gastroenteritis among infants and children—recommendations of
the Advisory Committee on Immunization Practices (ACIP). MMWR 2009;58(RR02):1-25. www.cdc.gov/mmwr/preview/mmwrhtml/
rr5802a1.htm (free access)
WHO.WHO position paper on rotavirus vaccines.Wkly Epidemiol Rec 2013;88:49-64. www.who.int/wer/2013/wer8805.pdf (free access)
Soares-Weiser K, MacLehose H, Bergman H, Ben-Aharon I, Nagpal S, Goldberg E, et al. Vaccines for preventing rotavirus diarrhoea:
vaccines in use. Cochrane Database Syst Rev 2012;11:CD008521 (subscription required)
PATH (http://sites.path.org/rotavirusvaccine/rotavirus-advocacy-and-communications-toolkit/)—Free rotavirus disease and vaccine
resources
PATH (http://sites.path.org/rotavirusvaccine/current-issue-of-rotaflash-jpg/)—Breaking news and updates on rotavirus vaccines
Resources for patients and parents
Centers for Disease Control and Prevention at (www.cdc.gov/rotavirus/index.html)—Basic information on the symptoms, treatment, and
prevention of rotavirus gastroenteritis
Tips for non-specialists
All children are infected with rotavirus in the first 3-5 years of life, regardless of hygiene and sanitation conditions
Vaccines are therefore the most effective way to prevent rotavirus diarrhea
Treatment of rotavirus diarrhea relies on hydration therapy
Rotavirus vaccines have performed well in countries where they are used routinely; in some settings, they have conferred additional
benefits to unvaccinated children and adults through herd protection
Although rotavirus vaccines work less well in developing countries, the potential to prevent severe disease and deaths is greater because
of the high disease burden in these settings
The documented health benefits of rotavirus vaccines far outweigh the small risk of intussusception that has been seen in some settings
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surveillance studies funded by GlaxoSmithKline and Pfizer.
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Tables
Table 1 | World Health Organization guidelines for assessing dehydration in children with acute gastroenteritis40
CBA
Condition*
Lethargic or unconsciousRestless, irritableWell, alert
Eyes†
SunkenSunkenNormal
Thirst
Drinks poorly, or not able to drinkThirsty, drinks eagerlyDrinks normally, not thirsty
Skin pinch‡
Skin goes back very slowlySkin goes back slowlySkin goes back quickly
Decision
Severe dehydration if there are ≥2 signs in CSome dehydration if there are ≥2 signs in BNo signs of dehydration
*Being lethargic and sleepy are not the same. A lethargic child is not simply asleep: the child’s mental state is dull and the child cannot be fully awakened; the
child may appear to be drifting into unconsciousness.
†In some infants and children the eyes normally appear somewhat sunken. It is helpful to ask the mother if the child’s eyes are normal or more sunken than usual.
‡The skin pinch is less useful in infants or children with marasmus or kwashiorkor, and in obese children.
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Table 2| Clinical dehydration scale32
Score*Characteristic
210
Drowsy, limp, and cold; may be comatoseThirsty, restless, or sleepy; irritable when touchedNormalGeneral appearance
Deeply sunkenSlightly sunkenNormalEyes
DryStickyMoistTongue
AbsentDecreasedPresentTears
*Total score: 0=no dehydration; 1-4=some dehydration; 5-8=moderate/severe dehydration.
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Table 3| Features of Rotarix and RotaTeq rotavirus vaccines
RotaTeqRotarixFeature
Five human G/P reassortants with bovine rotavirus strain WC3
(P7[5], G6): G1 × WC3; G2 × WC3; G3 × WC3; G3 × WC3;
P1A[8] × WC3
Single human rotavirus strain (P1A[8], G1)Composition
3 oral doses2 oral dosesNumber of doses needed
Dose 1: 6-12 weeks of age; doses 2 and 3: 4-10 week intervals;
complete by 32 weeks of age
Dose 1: minimum 6 weeks of age; dose 2: ≥4 weeks later;
complete by 24 weeks of age
Schedule*
Each dose (2 mL) contains at least 2.0-2.8×106 infectious units
per reassortant
Each dose (1-1.5 mL) contains at least 106 median cell culture
infectious doses
Dose
24 months36 monthsShelf life
2-8°C, protected from light2-8°C, protected from lightStorage
History of hypersensitivity to the vaccine or any component of
the vaccine; history of severe combined immunodeficiency
disease; history of intussusception
History of hypersensitivity to the vaccine or any component of
the vaccine; history of uncorrected congenital malformation of
the gastrointestinal tract that would predispose to intussusception;
history of severe combined immunodeficiency disease; history
of intussusception
Contraindications
*Ages for vaccine doses vary according to the recommendations of individual countries and vaccination schedules.
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Figures
Fig 1World Health Organization estimates of rotavirus mortality (deaths/100 000 children under 5 years of age) by country
in 2008. Reproduced, with permission, from Lancet Infectious Diseases2
Fig 2 Mechanisms of rotavirus pathogenesis. Most information on rotavirus pathogenesis is derived from small animal
models. Infection leads to attachment of the rotavirus to enterocytes (1), uncoating of the virus (2), followed by transcription
and translation of viral proteins (3). This leads to the formation of a viroplasm, from which double layered particles assemble
(4) and acquire outer coat proteins to form triple layered mature particles, which are shed by a non-classical secretory
pathway (5). The viral enterotoxin non-structural protein 4 (NSP4; red triangles) is also released with the mature virions.
NSP4 induces the release of intracellular calcium (Ca2+) (6) from the endoplasmic reticulum (ER) and disrupts tight junctions
(7), resulting in paracellular leakage of fluid and electrolytes. NSP4 can act on crypt cells to induce chloride (Cl−) secretion
directly (8) or through the enteric nervous system (ENS) (9), both of which draw water into the lumen. A decrease in brush
border enzymes induced by infection (10) results in accumulation of sugars in the lumen and osmotic fluid loss. Destruction
of intestinal cells later in infection results in loss of surface area and a malabsorptive diarrhea (11)
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